NCT04455516 is a clinical trial of Meniscus repair; partial meniscectomy in The ACL Rupture, sponsored by Peking University Third Hospital.

Who is sponsoring NCT04455516?

NCT04455516 is sponsored by Peking University Third Hospital.

What drugs are being tested in NCT04455516?

Interventions in NCT04455516: Meniscus repair; partial meniscectomy.

What condition does NCT04455516 study?

NCT04455516 studies The ACL Rupture, Meniscus Injury.

Is NCT04455516 still recruiting?

NCT04455516 is currently completed. Last updated 7 July 2020.

Last reviewed 2020-07-07 · How we verify

NCT04455516

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Meniscus Repair With Simultaneous ACL Reconstruction: Clinical Outcomes，Failure Rates And Subsequent Processing

Completed Last updated 7 July 2020

What this trial tests

trial testing Meniscus repair; partial meniscectomy in The ACL Rupture in 165 participants. Completed in 16 May 2020.

Timeline

16 March 2020

Primary endpoint
16 April 2020

16 May 2020

Quick facts

Lead sponsor	Peking University Third Hospital
Status	Completed
Study type	OBSERVATIONAL
Enrollment	165
Start date	16 March 2020
Primary completion	16 April 2020
Estimated completion	16 May 2020
Sites	1 location across China

Drugs / interventions tested

Meniscus repair; partial meniscectomy

Conditions studied

The ACL Rupture — all drugs for The ACL Rupture →
Meniscus Injury — all drugs for Meniscus Injury →

Sponsor

Peking University Third Hospital

Who can join

Adults 13 to 60, any sex, with The ACL Rupture or Meniscus Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Our study has explored the causes of failure of meniscus repair and investigated the clinical effects of partial meniscectomy when meniscus repair failed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Peking University Third Hospital trials

Trials by the same sponsor.

NCT07532421 — Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life · NA · not yet recruiting
NCT07470255 — Detection of Diabetic Foot Skin Damage Using Plantar Mechanical Parameters · not yet recruiting
NCT07453381 — Multisensor Wireless Pressure Microcatheter For Microvascular Function Assessment In ANOCA/INOCA Patients: A Prospective · not yet recruiting
NCT07452354 — AI-Based Diabetic Foot Recurrence Cohort · not yet recruiting
NCT07423819 — Sports Rehabilitation Therapy for Knee Joint Sports Injuries: A Case Study of Anterior Cruciate Ligament Injury and Pate · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04455516 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University Third Hospital
Last refreshed: 7 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04455516.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing